Title: Achieving Drug Costs that Wont Break the Bank
1Achieving Drug Costs that Wont Break the Bank
- Tom Reed, Unique Industries, Inc.
- Kevin OHara, Corporate Synergies Group, Inc.
2Overview
- Current State Of Prescription Drug Coverage
- Early Attempts at Moderating Costs
- Viewing Rx as an Independent Cost Driver
- Getting Aggressive
- Where Do We Go From Here?
3Historical Context
- Prescription Drugs vs. Other Medical Costs
- The Doubled-Edged Sword of Rx
- The Transition from Indemnity Models
- Ridered Prescription Benefits
- Co-Pay as a Reimbursement Strategy
4Recent Comparative Change
Source KFF/CMS
5Actual Underlying Rx Trend
Source Segal, 2006
6The Two-Edged Sword of Prescription Drugs
- Americans are clearly spending more each year on
prescriptions - The underlying cost of prescriptions has only
recently begun to moderate - Taking the necessary pharmaceutical agents today
will likely postpone or eliminate the need for
costly medical procedures in the future
7The Shoebox
- Major Medical-style programs dominated the
marketplace for the first 50 years of rx coverage - Deductible/Co-insurance mechanisms
- Built-in claims lag and submission suppression
- Operational inefficiency
8Co-Pay to the Rescue
- With the rise in co-pay-based medical programs,
the co-pay methodology gained a foothold in
prescription drugs - Easy-to administer and less burdensome on the
member - As with medical, tended to isolate the purchaser
from the underlying cost - Single tier plans predominated
9Shifting the Playing Field
- Split Co-Pays The Dynamics Begin to Change
- Separating and the Medical and Prescription
Elements - Administration of Prescription Benefits
- Carve-Out Rx and their Funding Models
10Split Co-Pays
- As the cost escalated and the availability of
less costly alternatives emerged, two-tier
co-pays became the norm - Reticence to accept the generic as
pharmacologically equivalent stymied early
acceptanceand continues today - Member and prescription drug manufacturer
workarounds arose Claritin/Clarinex
11Three Tiered Formularies
- Has become the standard
- Open Formulary/Mixed Model
- Demonstrated effect on trend
- Co-Pay Spread Issues
- Law of Unintended Consequences
- See Four Tiered Formulary
- See OTC
12Pharmacy Benefit Management
- The rise of PBMs
- Isolating the Rx and Medical elements
- Do what you do best
- Bulk Purchasing/Discounting
- Flexibility in Plan Design
- Network
- Care/Case Management
- Carve-Out Rx
13The Case for Carve-Out
- The Unique Industries Story
14Techniques
- Closed Formulary
- too Draconian?
- Transparency/Rebates
- Where does all the money go?
- What is the REAL underlying cost of the
prescription medication? - Carve-Out Injectibles
- Determine the medical coverage elements
- Where appropriate, shift obligation to the
medical carrier
15Techniques
- Benefit Statements for Rx
- Much like Total Comp or Hidden Paycheck
statements at year-end - Same Usefulness in Reinforcing Company
Contributions - Baseline Drug Formularies
- Lipitor/Crestor
- Setting the Cost by Drug and Shifting Focus
16Techniques
- Reverse Co-Pay
- Formulary establishes amount the COMPANY will pay
by therapeutic category - Highlights underlying drug costs and
pharmacological equivalents - Defining AWP/MAC
- Wide diversity of baselines
17Techniques
- Mandatory Generics
- Mandatory Mail
- Setting Co-Pay is Crticial
- The Magic Machine
- 50 mg and 100 mg Viagra 93.99 (drugstore.com)
- 20 mg, 40 mg and 80 mg Lipitor 116
(Walgreens) - REAL Consumer Driven Healthcare Employee-Shared
Savings
18Techniques
- Four Tiered Formularies
- Pitney-Bowes
- Five (and more) Tiered Formularies
- Re-Coupling Rx and Medical Care and Disease
Management - Predictive Disease Management Opportunities
- Facility of Data Exchange
19Techniques
- OTC Drug Coverage
- Nexium/Prilosec
- Step Therapy
- Age/Gender/Dosage Edits
- Re-Importation
- FSAs and Prescription Coverage
20Next?
- Global fees?
- Medicare as Single Source Payer?
- Determining Short-Filling?
- MERPs/HRAs for Prescription?